GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » Asset Turnover

TOVX (Theriva Biologics) Asset Turnover : 0.00 (As of Sep. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Theriva Biologics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Theriva Biologics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Theriva Biologics's Total Assets for the quarter that ended in Sep. 2024 was $41.25 Mil. Therefore, Theriva Biologics's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Theriva Biologics's annualized ROE % for the quarter that ended in Sep. 2024 was -118.22%. It is also linked to ROA % through Du Pont Formula. Theriva Biologics's annualized ROA % for the quarter that ended in Sep. 2024 was -74.92%.


Theriva Biologics Asset Turnover Historical Data

The historical data trend for Theriva Biologics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics Asset Turnover Chart

Theriva Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Theriva Biologics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Theriva Biologics's Asset Turnover

For the Biotechnology subindustry, Theriva Biologics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Asset Turnover falls into.



Theriva Biologics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Theriva Biologics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (71.861+55.219)/ 2 )
=0/63.54
=0.00

Theriva Biologics's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=0/( (42.39+40.108)/ 2 )
=0/41.249
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Theriva Biologics  (AMEX:TOVX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Theriva Biologics's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-30.904/26.1405
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-30.904 / 0)*(0 / 41.249)*(41.249/ 26.1405)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.578
=ROA %*Equity Multiplier
=-74.92 %*1.578
=-118.22 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Theriva Biologics's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-30.904/41.249
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-30.904 / 0)*(0 / 41.249)
=Net Margin %*Asset Turnover
= %*0
=-74.92 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Theriva Biologics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics Business Description

Traded in Other Exchanges
N/A
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Executives
Steven A Shallcross director, officer: CEO and CFO C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro officer: Chief Operating Officer 9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan director
Scott Tarriff director 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman officer: CHIEF MEDICAL OFFICER 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley director C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp 10 percent owner 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne officer: CHIEF FINANCIAL OFFICER 27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks director C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr director, officer: CEO & President C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome officer: Chief Scientific Officer 3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo director 509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman director
Wayne George Holman 10 percent owner 430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022

Theriva Biologics Headlines

From GuruFocus

Q2 2023 Theriva Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Could Insider Buying Signal that Theriva Biologics Inc Is Undervalued?

By GuruFocus Research GuruFocus Editor 01-23-2023

Q3 2023 Theriva Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q4 2023 Theriva Biologics Inc Earnings Call Transcript

By GuruFocus Research 03-26-2024

Q2 2021 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Could Insider Buying Signal that Theriva Biologics Inc Is Undervalued?

By GuruFocus Research GuruFocus Editor 02-03-2023

Q1 2019 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q4 2021 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2020 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024